Department of Gastrointestinal Surgery, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin 150081, China.
Department of Hepatopancreatobiliary Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin 150081, China.
Dis Markers. 2022 Mar 25;2022:2893336. doi: 10.1155/2022/2893336. eCollection 2022.
Gastric cancer (GC) might have significantly different outcomes within the same AJCC/UICC-TNM stage. The purpose of this study is to help predict the different prognosis through the pattern of immune cell infiltration. We retrospectively analyzed 2605 patients who underwent radical gastrectomy in the Harbin Medical University Cancer Hospital between 2002 and 2013. For stage III with significantly different survival probability, we analyzed the relationship between immune cell surface antigen and survival in TCGA dataset. Furthermore, 200 cases in stage III GC with different survival outcomes were randomly selected for immunohistochemical verification. Image Plus software was used to evaluate the area of immune cell infiltration. We found that patients in stage III had significantly different outcomes. Bioinformatics analysis showed that there was a significant negative correlation between the expression of immune cell surface antigen and prognosis. In order to investigate whether immune infiltration can distinguish GC patients in stage III with differences in prognosis, we verified by immunohistochemistry that CD4 T cells, CD20 B cells, and CD177 neutrophils infiltrated more in group B with better prognosis; CD8 T cells, CD68 macrophages, and CD117 mast cells infiltrated more in group A with poor prognosis. CD117 mast cells have the same trend of predicting significance for prognosis in the RNA and protein levels. In conclusion, patients with GC in northeastern China have significant prognostic differences only in stage III. CD117 mast cells may be important evaluation factors in further studies of Immunoscore.
胃癌(GC)在相同的 AJCC/UICC-TNM 分期内可能具有明显不同的结果。本研究旨在通过免疫细胞浸润模式帮助预测不同的预后。我们回顾性分析了 2002 年至 2013 年在哈尔滨医科大学肿瘤医院接受根治性胃切除术的 2605 例患者。对于具有显著不同生存概率的 III 期患者,我们在 TCGA 数据集分析了免疫细胞表面抗原与生存的关系。此外,我们随机选择了 200 例具有不同生存结果的 III 期 GC 患者进行免疫组织化学验证。使用 Image Plus 软件评估免疫细胞浸润面积。我们发现 III 期患者的生存结果有显著差异。生物信息学分析显示,免疫细胞表面抗原的表达与预后呈显著负相关。为了研究免疫浸润是否可以区分 III 期 GC 患者的预后差异,我们通过免疫组织化学验证发现,B 组预后较好的患者中 CD4 T 细胞、CD20 B 细胞和 CD177 中性粒细胞浸润更多;A 组预后较差的患者中 CD8 T 细胞、CD68 巨噬细胞和 CD117 肥大细胞浸润更多。CD117 肥大细胞在 RNA 和蛋白质水平上对预后的预测意义也具有相同的趋势。总之,中国东北地区的 GC 患者仅在 III 期具有显著的预后差异。CD117 肥大细胞可能是免疫评分进一步研究中的重要评估因素。